Evidence map›Paper›PMID 39204368›Full record

ArticlePharmaceutics2024

In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment.

Marika Faiella, Giada Botti, Alessandro Dalpiaz, Lorenzo Gnudi, Aurélie Goyenvalle, Barbara Pavan, Daniela Perrone, Matteo Bovolenta, Elena Marchesi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marika FaiellaDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Giada BottiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-2942-1437
Alessandro DalpiazDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-6648-2562
Lorenzo GnudiDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.
Aurélie GoyenvalleUniversity Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France.ORCID 0000-0003-3938-1165
Barbara PavanCenter for Translational Neurophysiology of Speech and Communication (CTNSC@UniFe), Italian Institute of Technology (IIT), 44121 Ferrara, Italy.ORCID 0000-0001-8942-9310
Daniela PerroneDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-5189-011X
Matteo BovolentaDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-9937-009X
Elena MarchesiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-5402-4732

Funding

University of Ferrara 2022-FAR.L-DA_018, A.D.; 2022-FAR.L-PB_001, B.P.; 2022-FAR.L-PD, D.P.; 2022-FAR.L-BM, M.B., 2021-FIRD M.B. and 2021-DOTT-DM-1061_FM_01_RIC, M.B
6 · The paper itself

Abstract

Delivery represents a major hurdle to the clinical advancement of oligonucleotide therapeutics for the treatment of disorders such as Duchenne muscular dystrophy (DMD). In this preliminary study, we explored the ability of 2'-

Indexed as

antisense oligonucleotidesco-cultureconjugated oligonucleotidesDMD myotubesDuchenne muscular dystrophyexon skippingexosomesIEC-6 cellsintestinal permeationursodeoxycholic acid

Identifiers

PMID39204368
PMCPMC11360444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.